KR20030068698A - Whitening cosmetic composition containing nano multiple lamella sphere and method of producing the same - Google Patents
Whitening cosmetic composition containing nano multiple lamella sphere and method of producing the same Download PDFInfo
- Publication number
- KR20030068698A KR20030068698A KR1020020008280A KR20020008280A KR20030068698A KR 20030068698 A KR20030068698 A KR 20030068698A KR 1020020008280 A KR1020020008280 A KR 1020020008280A KR 20020008280 A KR20020008280 A KR 20020008280A KR 20030068698 A KR20030068698 A KR 20030068698A
- Authority
- KR
- South Korea
- Prior art keywords
- lamellar
- micromultiple
- globules
- weight
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 58
- 239000002537 cosmetic Substances 0.000 title claims abstract description 40
- 230000002087 whitening effect Effects 0.000 title claims abstract description 39
- 241000446313 Lamella Species 0.000 title claims abstract description 8
- 238000000034 method Methods 0.000 title claims description 22
- 239000002502 liposome Substances 0.000 claims abstract description 10
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 46
- 235000012000 cholesterol Nutrition 0.000 claims description 23
- 239000003921 oil Substances 0.000 claims description 22
- 235000019198 oils Nutrition 0.000 claims description 22
- 239000004480 active ingredient Substances 0.000 claims description 21
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 20
- 229940106189 ceramide Drugs 0.000 claims description 18
- 230000001434 glomerular Effects 0.000 claims description 18
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims description 16
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims description 16
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims description 16
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims description 16
- 238000010438 heat treatment Methods 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 235000011187 glycerol Nutrition 0.000 claims description 10
- 239000008213 purified water Substances 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000000284 extract Substances 0.000 claims description 9
- ZUVCYFMOHFTGDM-UHFFFAOYSA-N hexadecyl dihydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCOP(O)(O)=O ZUVCYFMOHFTGDM-UHFFFAOYSA-N 0.000 claims description 7
- 235000015097 nutrients Nutrition 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- 241000220317 Rosa Species 0.000 claims description 4
- 235000020710 ginseng extract Nutrition 0.000 claims description 4
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 claims description 3
- 239000009429 Ginkgo biloba extract Substances 0.000 claims description 3
- 240000008415 Lactuca sativa Species 0.000 claims description 3
- 235000003228 Lactuca sativa Nutrition 0.000 claims description 3
- 235000018330 Macadamia integrifolia Nutrition 0.000 claims description 3
- 240000000912 Macadamia tetraphylla Species 0.000 claims description 3
- 235000003800 Macadamia tetraphylla Nutrition 0.000 claims description 3
- 229940086555 cyclomethicone Drugs 0.000 claims description 3
- 229940008099 dimethicone Drugs 0.000 claims description 3
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims description 3
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 239000010466 nut oil Substances 0.000 claims description 3
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 3
- 229940068052 ginkgo biloba extract Drugs 0.000 claims description 2
- 235000020686 ginkgo biloba extract Nutrition 0.000 claims description 2
- 244000269722 Thea sinensis Species 0.000 claims 2
- 238000004090 dissolution Methods 0.000 claims 2
- 239000008406 cosmetic ingredient Substances 0.000 abstract description 4
- 239000002994 raw material Substances 0.000 abstract description 4
- 210000003491 skin Anatomy 0.000 description 29
- 238000002360 preparation method Methods 0.000 description 26
- 230000000052 comparative effect Effects 0.000 description 19
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 16
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 14
- 239000008186 active pharmaceutical agent Substances 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 230000008099 melanin synthesis Effects 0.000 description 9
- 229960000271 arbutin Drugs 0.000 description 8
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 8
- 229960005070 ascorbic acid Drugs 0.000 description 7
- 235000010323 ascorbic acid Nutrition 0.000 description 7
- 239000011668 ascorbic acid Substances 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 6
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 4
- 102000003425 Tyrosinase Human genes 0.000 description 4
- 108060008724 Tyrosinase Proteins 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 210000002752 melanocyte Anatomy 0.000 description 4
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- 229940058015 1,3-butylene glycol Drugs 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
- 230000002421 anti-septic effect Effects 0.000 description 3
- 230000003796 beauty Effects 0.000 description 3
- 235000019437 butane-1,3-diol Nutrition 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 3
- 229960004705 kojic acid Drugs 0.000 description 3
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 3
- 229940069445 licorice extract Drugs 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 230000019612 pigmentation Effects 0.000 description 3
- 239000000230 xanthan gum Substances 0.000 description 3
- 229920001285 xanthan gum Polymers 0.000 description 3
- 229940082509 xanthan gum Drugs 0.000 description 3
- 235000010493 xanthan gum Nutrition 0.000 description 3
- 241000700198 Cavia Species 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000001382 Experimental Melanoma Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 2
- 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 description 2
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001783 ceramides Chemical class 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- OHVLMTFVQDZYHP-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CN1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O OHVLMTFVQDZYHP-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229910001431 copper ion Inorganic materials 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 230000037312 oily skin Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 238000010865 video microscopy Methods 0.000 description 1
- 229910052724 xenon Inorganic materials 0.000 description 1
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0295—Liquid crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/68—Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Cosmetics (AREA)
Abstract
본 발명은 피부 활성 미용 성분과 오일 성분을 리포좀화시킨 미세다중 라멜라 소구체(Nano Multiple Lamella Sphere)를 포함하는 미백 화장료 조성물에 관한 것으로서, 이러한 화장료 조성물은 기존 미백 원료를 이용한 화장료 조성물에 비해 훨씬 상승된 미백 효과와 우수한 피부 안정성을 나타낸다.The present invention relates to a whitening cosmetic composition comprising a nano-multiple lamella spheres liposomes of skin active cosmetic ingredients and oil components, which is much higher than the cosmetic composition using a conventional whitening raw material. Whitening effect and excellent skin stability.
Description
본 발명은 미백 화장료 조성물에 관한 것으로서, 보다 구체적으로 피부 활성 미용 성분과 오일 성분을 리포좀화시킨 미세다중 라멜라 소구체(Nano Multiple Lamella Sphere)를 함유하는 미백 화장료 조성물 및 그 제조 방법에 관한 것이다.BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a whitening cosmetic composition, and more particularly, to a whitening cosmetic composition containing a nano multiple lamella sphere obtained by liposome-forming a skin active cosmetic ingredient and an oil ingredient, and a method for producing the same.
일반적으로 사람의 피부가 검게 변화되는 것은 여러 가지 원인을 들 수 있지만, 주된 요인은 자외선에 피부가 노출되었을 때 피부세포의 일종인 멜라노사이트 (Melanocyte)내에서 멜라닌(Melanin)의 합성이 증가되고 방출되기 때문이라고 알려져있다. 멜라노사이트에서 멜라닌이 합성되는 과정을 구체적으로 살펴보면, 세포내의 티로신(Tyrosine)을 기질로 하여 티로시나아제(Tyrosinase)라는 효소가 작용하고, 이에 따라 도파퀴논(Dopaquinone)을 생성시키며 도파퀴논으로부터 자발적인 반응과 효소반응을 거쳐 공중합체 흑색 색소 멜라닌이 생성된다. 따라서 피부가 검게되는 것을 막기 위해서는 멜라닌 생성과정 중의 일부 반응을 억제시킴으로써 멜라닌의 생성을 감소시켜 주는 방법이 일반적이며 용이하다고 할 수 있다.In general, the blackening of the human skin may have various causes, but the main factor is the increase and release of melanin synthesis in melanocytes, a type of skin cells when the skin is exposed to ultraviolet rays. Because it is known. Looking specifically at the process of melanin synthesis in melanocytes, the enzyme tyrosinase (Tyrosinase) acts as a substrate to the intracellular tyrosine (Tyrosinase) acts, thereby producing dopaquinone (Dopaquinone) and spontaneous reaction from dopaquinone Copolymer black pigment melanin is produced through the enzymatic reaction. Therefore, in order to prevent skin blackening, it is general and easy to reduce melanin production by inhibiting some reactions during melanin production.
이를 위해 종래에는 아스콜빈산(Ascorbic acid), 코직산(Kojic acid), 알부틴(Arbutin), 하이드로퀴논(Hydroquinone), 유용성 감초산 추출물(Licorice extract) 및 각종 식물 추출물 등이 사용되어 왔다. 이들 중에서 코직산은 티로시나아제의 활성부위에 존재하는 구리이온을 킬레이트시켜 효소활동을 저해하는 작용을 하는데, 성능이 좋은 반면 화장품에 배합시 안정성에 문제점이 있어 사용하는데 부적절하며, 하이드로퀴논은 피부에 대한 자극성이 높아 안전성 문제로 인하여 현재 화장료로 사용하지 못하고 있다. 따라서 일반적으로 알부틴이나 유용성 감초 추출물을 이용한 화장품이 주류를 이루고 있다.To this end, conventionally, ascorbic acid (Ascorbic acid), kojic acid (Kojic acid), arbutin (Arbutin), hydroquinone (Hydroquinone), oil-soluble licorice extract (Licorice extract) and various plant extracts have been used. Of these, kojic acid chelates copper ions in the active site of tyrosinase and inhibits enzymatic activity.They have good performance, but are not suitable for use because they have problems in stability when formulated in cosmetics. Due to its high irritation, it is currently not used as a cosmetic due to safety issues. Therefore, in general, cosmetics using arbutin or oil-soluble licorice extract is the mainstream.
이와 같은 종래 화장료 조성물들은 미백 효과를 부여하기 위해서 반드시 미백 효과를 갖는 원료를 사용해야만 한다는 한계를 가지고 있다. 이에 본 발명자들은 기존의 미백 원료가 아닌 의약계에서 널이 응용되고 있는 약물전달체계(Drug Delivery System)에 의한 피부활성 성분의 리포좀(Liposome)화 방법이라는 새로운 적용 방법을 시도를 하였다.Such conventional cosmetic compositions have a limitation that a raw material having a whitening effect must be used in order to give a whitening effect. Therefore, the present inventors have tried a new application method of liposome formation method of the skin active ingredient by the drug delivery system (Drug Delivery System) that is applied in the pharmaceutical system rather than the existing whitening raw materials.
특히 본 발명은 본 발명자들이 개발하여 특허등록을 받은 국내 특허제115076호 "미세다중 라멜라 소구체 구조의 유화상 화장품 및 그 제조방법"을 기초로 하여 이에 미백 기능을 추가로 부여한 것으로서 다양한 기능성 화장료 조성물의 지속적인 개발이라는 일련의 과정 중에 얻어진 성과이다.In particular, the present invention is based on the domestic patent No.115076, which has been developed and registered by the inventors of the present invention, based on the "emulsified cosmetics of fine multi-lamellar globules and a method for manufacturing the same" . Achievements made during the process of continuous development.
본 발명의 목적은 세라마이드(Ceramides), 콜레스테롤(Cholesterol), 시토스테롤(Sitosterol)을 함유하는 제1차 미세다중 라멜라 소구체 조성물에 오일 성분 또는 피부활성 성분을 첨가한 후 고압미세균질기를 이용하여 리포좀화시킨 것을 특징으로 하는 우수한 미백 기능을 갖는 제2차 미세다중 라멜라 소구체 조성물 및 그 제조 방법을 제공하는 것이다.An object of the present invention is to add liposomes using a high pressure micro homogenizer after adding an oil component or an active skin component to a first micromultiple lamellar glomerular composition containing ceramides, cholesterol, and cytosterol. It is to provide a secondary micromultiple lamellar glomerular composition and a method for producing the same having excellent whitening function.
본 발명의 또다른 목적은 세라마이드, 콜레스테롤, 시토스테롤을 함유하는 제1차 미세다중 라멜라 소구체 조성물에 피부활성 성분을 첨가한 후 고압미세균질기를 이용하여 제2차 미세다중 라멜라 소구체 조성물을 형성시킨 다음, 또 다시 오일 성분을 첨가한 후 고압미세균질기를 이용하여 리포좀화시킨 것을 특징으로 하는 탁월한 미백 기능을 갖는 제3차 미세다중 라멜라 소구체 조성물 및 그 제조 방법을 제공하는 것이다.It is another object of the present invention to add a skin active ingredient to the first micromultiple lamellar globule composition containing ceramide, cholesterol and cytosterol, and then to form the second micromultiple lamellar globule composition using a high pressure micro homogenizer. Next, to provide a third fine multi-lamellar globule composition having excellent whitening function, characterized in that the liposomes using a high-pressure micro homogenizer after the addition of the oil component and a method for producing the same.
궁극적으로 본 발명은 위와 같은 제2차 또는 제3차 미세다중 라멜라 소구체를 유효량 함유하는 미백 기능성 화장료 조성물을 제공하는 것을 목적으로 한다.Ultimately, the present invention aims to provide a whitening functional cosmetic composition containing an effective amount of the secondary or tertiary micromultiple lamellar globules as described above.
도 1은 B-16 멜라닌 세포를 이용하여 본 발명에 따른 미세다중 라멜라 소구체 조성물의 멜라닌 세포 생성 억제율을 육안으로 판정한 결과를 나타낸 사진이다.1 is a photograph showing the results of visually determining the melanocyte production inhibition rate of the micromultiple lamellar glomerular composition according to the present invention using B-16 melanocytes.
도 2는 갈색 기니아 피그를 이용하여 본 발명에 따른 미세다중 라멜라 소구체 조성물의 색소 침착의 개선 효과 결과를 나타낸 그래프이다.Figure 2 is a graph showing the improvement effect of the pigmentation of the micromultiple lamellar glomerular composition according to the present invention using a brown guinea pig.
본 발명은 세라마이드, 콜레스테롤, 시토스테롤을 함유하는 제1차 미세다중 라멜라 소구체 조성물에 오일 성분 또는 피부활성 성분을 첨가한 후 고압미세균질기를 이용하여 리포좀화시킨 것을 특징으로 하는 우수한 미백 기능을 갖는 제2차미세다중 라멜라 소구체 조성물 및 그 제조 방법에 관한 것이다.The present invention is an agent having excellent whitening function, characterized in that the liposome is formed using a high pressure micro homogenizer after adding an oil component or an active skin component to the first micromultiple lamella globule composition containing ceramide, cholesterol and cytosterol. A secondary fine polylamellar globule composition and a method for producing the same.
세라마이드, 콜레스테롤, 시토스테롤을 함유하는 일반적인 미세다중 라멜라 소구체 조성물은 피부도포시 미용성분의 피부침투력을 높이고, 미용성분의 단계적인 방출을 통해 미용 효과의 지속력을 높일 수 있으며, 화장품에 다량의 미용성분을 함유할 수 있도록 하기 때문에 매우 유용한 화장료로 알려져 있다((주)한국화장품 특허 제115076호 "미세다중 라멜라 소구체 구조의 유화상 화장품 및 그 제조방법").The general micro-multiple lamella globule composition containing ceramide, cholesterol, and cytosterol can increase skin penetration of beauty ingredients during skin application, increase the sustainability of beauty effects through the stepwise release of beauty ingredients, and a large amount of cosmetic ingredients in cosmetics. It is known as a very useful cosmetic because it can contain ( Korean cosmetics patent No. 115076 "Emulsion cosmetics of fine multi-lamellar globule structure and its manufacturing method" ).
본 발명은 상기 발명을 기초로 화장료의 기제에 인체의 피부 각질층의 세포간 지질과 유사한 성분인 양친매성 천연지질, 세라마이드, 천연유화제인 시토스테롤 및 콜레스테롤을 일정구성비로 함유시켜 미세다중 라멜라 소구체를 형성시키고, 이 미세다중 라멜라 소구체에 피부활성 성분인 장미꽃잎 추출물(Vegetol Rose extract), 상백피 추출물(Mulberry extract), 은행잎 추출물(Gingkobiloba extract) 및 인삼 추출물(Ginseng extract)을 미세다중 라멜라 소구체 형태로 감싸도록 함으로써 피부침투력이 뛰어나며, 피부에 대한 효능·효과 및 지속성이 우수하고, 특히 피부 안전성 및 미백효과를 부여하는 미세다중 라멜라 소구체 구조를 갖는 미백화장료를 제공하는데 있다.The present invention is based on the present invention to form a micro-multiple lamella globules by containing a certain ratio of amphiphilic natural lipids, ceramides, natural emulsifiers cytosterol and cholesterol in the base of the cosmetic composition similar to the intercellular lipids of the stratum corneum of the human body To the micromultiple lamellar globules, the skin active ingredients, Vegetol Rose extract, Mulberry extract, Gingkobiloba extract and Ginseng extract, were obtained in the form of micromultiple lamellar globules. The present invention provides a whitening cosmetic having a fine multi-lamellar globule structure that is excellent in skin penetration, excellent in efficacy, effect, and sustainability on the skin, and particularly imparts skin safety and whitening effect.
본 발명에 사용되는 미세다중 라멜라 소구체의 각 구성성분의 함량은 세라마이드 0.1∼10.0 중량%, 콜레스테롤 0.5∼15.0%, 시토스테롤 1.0∼15.0 중량%인 것이 바람직하다.The content of each component of the micromultiple lamellar globules used in the present invention is preferably 0.1 to 10.0% by weight of ceramide, 0.5 to 15.0% of cholesterol, and 1.0 to 15.0% by weight of cytosterol.
또한 본 발명에 포함되는 상기 오일 성분은 마카다미아 넛 오일, 사이클로메치콘, 디메치콘 또는 이들의 혼합물 중에서 선택되는 것이 바람직하며, 오일 성분의 함량은 전체 조성물의 1~ 20 중량%인 것이 바람직하다.In addition, the oil component included in the present invention is preferably selected from macadamia nut oil, cyclomethicone, dimethicone or a mixture thereof, and the content of the oil component is preferably 1 to 20% by weight of the total composition.
또한 본 발명에 포함되는 상기 피부활성 성분은 장미꽃잎 추출물, 상백피 추출물, 은행잎 추출물, 인삼 추출물 또는 이들의 혼합물 중에서 선택되는 것이 바람직하며, 이러한 피부활성 성분의 함량은 전체 조성물의 1 ~ 30 중량%인 것이 바람직하다.In addition, the skin active ingredient included in the present invention is preferably selected from rose leaf extract, lettuce extract, ginkgo biloba extract, ginseng extract or a mixture thereof, the content of such skin active ingredient is 1 to 30% by weight of the total composition It is preferable.
본 발명은 위에서 설명한 것과 같이, 일반적인 미세다중 라멜라 소구체 조성물에 오일 성분 또는 피부활성 성분을 선택적으로 첨가하여 이를 고압미세균질기를 이용하여 리포좀 구조화시키는 것에 만족하지 않고, 오일 성분과 피부활성 성분을 순차적으로 리포좀 구조화시켜 제3차 미세다중 라멜라 소구체 조성물을 형성시킴으로써 이러한 조성물이 두 성분의 상승 효과(Synergy)에 의해 보다 우수한 미백 효과를 나타냄을 밝혀내었다.As described above, the present invention is not satisfied to selectively add an oil component or a skin active ingredient to a general micromultiple lamellar glomerular composition and to structure the liposome using a high pressure micro homogenizer, and to sequentially process the oil component and the skin active ingredient. Liposome structured to form a tertiary micromultiple lamellar glomerular composition revealed that this composition exhibited a better whitening effect by synergy of the two components.
이와 같이 오일 성분과 피부활성 성분을 모두 포함하는 미세다중 라멜라 소구체 조성물에 사용되는 오일 성분 및 피부활성 성분의 종류와 함량은 위에서 기재한 바와 같다.As described above, the type and content of the oil component and the skin active ingredient used in the micromultiple lamellar glomerular composition including both the oil component and the skin active ingredient are as described above.
이하 실시예를 통하여 본 발명을 보다 상세히 설명하기로 한다. 단, 하기 실시예는 본 발명을 예시하기 위한 것으로서 본 발명의 범위가 실시예에 한정되는 것으로 해석되는 것은 허용되지 않는다.Hereinafter, the present invention will be described in more detail with reference to the following examples. However, the following examples are provided to illustrate the present invention, and the scope of the present invention is not to be construed as being limited to the examples.
제조예 1Preparation Example 1
세라마이드, 콜레스테롤, 시토스테롤을 함유하는 제1차 미세다중 라멜라 소구체 조성물에 오일 성분이 첨가된 제2차 미세다중 라멜라 소구체 조성물을 제조하는 방법은 다음 단계들을 포함한다.The method for preparing a secondary micromultiple lamellar globule composition in which an oil component is added to the primary micromultiple lamellar globule composition containing ceramide, cholesterol and cytosterol comprises the following steps.
(a) 정제수 일부량과 농글리세린, 세틸포스페이트 및 그 염류를 60∼100℃로 가열 용해한다.(a) A portion of purified water, concentrated glycerin, cetylphosphate and salts thereof are dissolved by heating to 60 to 100 ° C.
(b) 콜레스테롤, 시토스테롤, 세테스, 세라마이드를 용해부에서 용제 또는 가열법을 이용하여 친매화시킨다.(b) Cholesterol, cholesterol, cytosterol, cethes and ceramide are dissolved in the dissolving unit by using a solvent or heating method.
(c) (a)과 (b)에서 용해된 성분들을 60∼150℃에서 습윤시키고 40∼80℃의 온도로 냉각한 후, 200∼1,000 Bar의 압력을 유지하면서 고압미세균질기를 이용하여 미세다중 라멜라 소구체 구조를 형성시킨다.(c) The components dissolved in (a) and (b) were wetted at 60 to 150 ° C. and cooled to a temperature of 40 to 80 ° C., followed by micromultiple using a high pressure micro homogenizer while maintaining a pressure of 200 to 1,000 Bar. To form a lamellae globule structure.
(d) 상기 미세다중 라멜라 소구체 조성물에 오일 성분을 첨가하여 균질하게 한 후, 2차 고압미세균질기를 통과시켜 미세다중 라멜라 소구체화시킨다.(d) After homogenizing by adding an oil component to the micromultiple lamellar glomerular composition, it is passed through a secondary high pressure microhomogenizer to micromultiple lamellar glomeruli.
제조예 2Preparation Example 2
세라마이드, 콜레스테롤, 시토스테롤을 함유하는 제1차 미세다중 라멜라 소구체 조성물에 피부활성 성분이 첨가된 제2차 미세다중 라멜라 소구체 조성물을 제조하는 방법은 다음 단계들을 포함한다.The method for preparing a secondary micromultiple lamellar globule composition in which a skin active ingredient is added to the primary micromultiple lamellar globule composition containing ceramide, cholesterol and cytosterol comprises the following steps.
(a) 정제수 일부량과 농글리세린, 세틸포스페이트 및 그 염류를 60∼100℃로 가열 용해한다.(a) A portion of purified water, concentrated glycerin, cetylphosphate and salts thereof are dissolved by heating to 60 to 100 ° C.
(b) 콜레스테롤, 시토스테롤, 세테스, 세라마이드를 용해부에서 용제 또는 가열법을 이용하여 친매화시킨다.(b) Cholesterol, cholesterol, cytosterol, cethes and ceramide are dissolved in the dissolving unit by using a solvent or heating method.
(c) (a)과 (b)에서 용해된 성분들을 60∼150℃에서 습윤시키고 40∼80℃의 온도로 냉각한 후, 200∼1,000Bar의 압력을 유지하는 고압미세균질기를 이용하여 미세다중 라멜라 소구체 구조를 형성시킨다.(c) The components dissolved in (a) and (b) were wetted at 60 to 150 ° C., cooled to a temperature of 40 to 80 ° C., and then micromultiple using a high pressure micro homogenizer maintaining a pressure of 200 to 1,000 Bar. To form a lamellae globule structure.
(d) 상기 미세다중 라멜라 소구체 조성물에 피부활성 성분을 첨가하여 균질하게 한 후, 2차 고압미세균질기를 통과시켜 미세다중 라멜라 소구체화 시킨다.(d) After adding a skin active ingredient to the micromultiple lamellar glomerular composition to make it homogeneous, it is passed through a second high pressure microhomogenizer to micromultiple lamellar glomeruli.
제조예 3Preparation Example 3
세라마이드, 콜레스테롤, 시토스테롤을 함유하는 제1차 미세다중 라멜라 소구체 조성물에 피부활성 성분과 오일 성분을 순차적으로 첨가하여 미세다중 라멜라 소구체 조성물을 제조하는 방법은 다음 단계들을 포함한다.The method for preparing the micromultiple lamellar glomerular composition by sequentially adding the skin active ingredient and the oil component to the first micromultiple lamellar globule composition containing ceramide, cholesterol, and cytosterol includes the following steps.
(a) 정제수 일부량과 농글리세린, 세틸포스페이트 및 그 염류를 60∼100℃로 가열 용해한다.(a) A portion of purified water, concentrated glycerin, cetylphosphate and salts thereof are dissolved by heating to 60 to 100 ° C.
(b) 콜레스테롤, 시토스테롤, 세테스, 세라마이드를 용해부에서 용제 또는 가열법을 이용하여 친매화시킨다.(b) Cholesterol, cholesterol, cytosterol, cethes and ceramide are dissolved in the dissolving unit by using a solvent or heating method.
(c) (a)과 (b)에서 용해된 성분들을 60∼150℃에서 습윤시키고 40∼80℃의 온도로 냉각한 후, 200∼1,000Bar의 압력을 유지하는 고압미세균질기를 이용하여 제1차 미세다중 라멜라 소구체 구조를 형성시킨다.(c) the components dissolved in (a) and (b) were moistened at 60 to 150 ° C. and cooled to a temperature of 40 to 80 ° C., followed by a high pressure micro homogenizer maintaining a pressure of 200 to 1,000 Bar. Primary micromultiple lamellar glomerular structures are formed.
(d) 상기 미세다중 라멜라 소구체 조성물에 미용활성 성분을 첨가하여 균질하게 한 후, 2차 고압미세균질기를 통과시켜 제2차 미세다중 라멜라 소구체 조성물을 제조한다.(d) adding a cosmetically active ingredient to the micromultiple lamellar glomerular composition to make it homogeneous, and then passing the secondary high pressure microhomogenizer to prepare a second micromultiple lamellar glomerular composition.
(e) 상기 제2차 조성물에 오일 성분을 첨가하여 균질하게 한 후, 고압미세균질기를 통과시켜 제3차 미세다중 라멜라 소구체를 유화상화시킨다.(e) After homogenizing by adding an oil component to the secondary composition, the third micromultiple lamellar globules are emulsified by passing through a high pressure micro homogenizer.
이어서, 상기 제조예 1, 2, 3에서 형성된 미세다중 라멜라 소구체에 대한 멜라닌 생성억제율을 실험하였다.Subsequently, the melanin production inhibition rate of the micromultiple lamellar globules formed in Preparation Examples 1, 2, and 3 was examined.
실험예 1: 멜라닌 생성억제율Experimental Example 1: Melanin Production Inhibition Rate
제조예 1, 2, 3에서 제조한 미세다중 라멜라 소구체에 대하여 B-16 Melanoma cell(원주의과대학 분양)을 이용한 미백효과를 측정하였다. 측정방법으로는 Black mouse로부터 유래된 B-16 melanoma cell을 10% FBS(GIBCO Ltd., 미국)가 함유된 DMEM medium(GIBCO Ltd., 미국)으로 96 Well Tissue Culture Plate(NUNC사, 덴마크)에 2×104cells/well 농도로 2mL씩 첨가하고 5% CO2, 37℃ 조건하에서 24시간 배양하였다. 배양 후 배지를 제거하고 10% FBS, 2uM α-MSH(Melanocyte Stimulating Hormone)(SIGMA사, 미국), 2mM theophilline(SIGMA사, 미국)이 함유된 DMEM으로 교체한 다음, 미세다중 라멜라 소구체를 같은 배지로 적당히 희석하여 첨가한 후 5% CO2, 37℃ 조건하에서 세포가 well의 바닥에 dir 80% 이상 될 때까지 배양하였다.The whitening effect of the micromultiple lamellar globules prepared in Preparation Examples 1, 2, and 3 using B-16 Melanoma cell (Wonju Medical University) was measured. As a measuring method, B-16 melanoma cells derived from black mice were placed on 96 Well Tissue Culture Plate (NUNC, Denmark) with DMEM medium (GIBCO Ltd., USA) containing 10% FBS (GIBCO Ltd., USA). 2 mL each was added at a concentration of 2 × 10 4 cells / well and incubated for 24 hours under conditions of 5% CO 2 and 37 ° C. After incubation, the medium was removed and replaced with DMEM containing 10% FBS, 2uM α-MSH (Melanocyte Stimulating Hormone) (SIGMA, USA), 2 mM theophilline (SIGMA, USA), and the micromultiple lamellar globules were replaced with the same. After proper dilution with medium, the cells were cultured under 5% CO2 and 37 ° C until the cells were at least 80% dir at the bottom of the well.
배양 후 배지를 제거한 다음 PBS로 세척하고 trypsin처리하여 세포 pellet을 회수하였다. 회수된 pellet을 effendrof tube로 옮겨 10,000rpm으로 10분간 원심분리한 다음 상등액을 제거하였다. 상등액이 제거된 pellet을 60℃에서 건조하였다. 건조후 pellet에 1N NaOH를 첨가하여 세포내의 melanin을 용해시켰다. 용해된 melanin을 PBS로 적당량 희석하여 ELISA reader(UV max, MOLECULAR DEVICES사, 미국)로 490㎚에서 흡광도를 측정하고 각 제조예에서 (3)번 공정에 의해서 제조된 미세다중 라멜라 소구체를 대조군으로 하고 제조예 1, 2, 3의 미세다중 라멜라 소구체의 melanin 생성억제율을 구하였다(표 1 참조). 또한, video microscopy로 사진촬영 후 육안 판정하였다(도 1 참조).After incubation, the medium was removed, washed with PBS and treated with trypsin to recover the cell pellet. The recovered pellet was transferred to an effendrof tube, centrifuged at 10,000 rpm for 10 minutes, and the supernatant was removed. The pellet from which the supernatant was removed was dried at 60 ° C. After drying, 1N NaOH was added to the pellet to dissolve melanin in the cells. Dilute the appropriate amount of melanin with PBS and measure the absorbance at 490 nm with ELISA reader (UV max, MOLECULAR DEVICES, USA), and use the micromultiple lamellar globules prepared by step (3) in each preparation as a control. Inhibition rate of melanin production of the micromultiple lamellar glomeruli of Preparation Examples 1, 2 and 3 was determined (see Table 1). In addition, visual observation after photographing by video microscopy (see Fig. 1).
실험예 1의 비교 실험을 통해 미세다중 라멜라 소구체를 갖는 대조군과 제조예 1의 미세다중 라멜라 소구체가 미백효과가 있음을 알 수 있었고, 특히 미용 활성 성분을 포함한 제조예 2, 3이 대조군과 제조예 1 보다 미백효과에 있어서 상승 효과(Synergy)가 있음을 알 수 있었다.The comparative experiments of Experimental Example 1 showed that the control group and the micromultiple lamellar glomeruli of Preparation Example 1 had a whitening effect, and in particular, Preparation Examples 2 and 3 containing cosmetic active ingredients were compared with the control group. It was found that there was a synergistic effect (Synergy) in the whitening effect than in Preparation Example 1.
본 발명의 미세다중 소구체(제조예 1, 2, 3)와 기존 미백원료를 미세다중 라멜라 소구체화한 것에 대한 세포독성 테스트를 실험예 2에 표시하였다.The cytotoxicity test for the micromultiple lamellar glomeruli of the micromultiple glomeruli (Preparation Examples 1, 2, 3) and the existing whitening material of the present invention is shown in Experimental Example 2.
기존 미백원료를 미세다중 라멜라 소구체화하여 제조하는 예는 아래와 같다.An example of manufacturing the existing whitening material by micromultiple lamellar glomeruli is as follows.
제조예 4Preparation Example 4
(a) 정제수 일부량과 농글리세린, 세틸포스페이트 및 그 염류를 60∼100℃로 가열 용해한다.(a) A portion of purified water, concentrated glycerin, cetylphosphate and salts thereof are dissolved by heating to 60 to 100 ° C.
(b) 콜레스테롤, 시토스테롤, 세테스, 세라마이드를 용해부에서 용제 또는 가열법을 이용하여 친매화시킨다.(b) Cholesterol, cholesterol, cytosterol, cethes and ceramide are dissolved in the dissolving unit by using a solvent or heating method.
(c) (1)과 (2)에서 용해된 성분들을 60∼150℃에서 습윤시키고 40∼80℃의 온도로 냉각한 후, 200∼1,000Bar의 압력을 유지하는 고압미세균질기를 이용하여 미세다중 라멜라 소구체 구조를 형성시킨다.(c) The components dissolved in (1) and (2) were wetted at 60 to 150 ° C., cooled to a temperature of 40 to 80 ° C., and then micromultiple using a high pressure micro homogenizer maintaining a pressure of 200 to 1,000 Bar. To form a lamellae globule structure.
(d) 알부틴 성분을 첨가하여 균질하게 한 후, 2차 고압미세균질기를 통과시켜 미세다중 라멜라 소구체화시켰다.(d) After homogenization by addition of the arbutin component, it was passed through a secondary high-pressure microhomogenizer to micromultiple lamellar glomeruli.
제조예 5Preparation Example 5
(a) 정제수 일부량과 농글리세린, 세틸포스페이트 및 그 염류를 60∼100℃로 가열 용해한다.(a) A portion of purified water, concentrated glycerin, cetylphosphate and salts thereof are dissolved by heating to 60 to 100 ° C.
(b) 콜레스테롤, 시토스테롤, 세테스, 세라마이드를 용해부에서 용제 또는 가열법을 이용하여 친매화시킨다.(b) Cholesterol, cholesterol, cytosterol, cethes and ceramide are dissolved in the dissolving unit by using a solvent or heating method.
(c) (a)과 (b)에서 용해된 성분들을 60∼150℃에서 습윤시키고 40∼80℃의 온도로 냉각한 후, 200∼1,000Bar의 압력을 유지하는 고압미세균질기를 이용하여 미세다중 라멜라 소구체 구조를 형성시킨다.(c) The components dissolved in (a) and (b) were wetted at 60 to 150 ° C., cooled to a temperature of 40 to 80 ° C., and then micromultiple using a high pressure micro homogenizer maintaining a pressure of 200 to 1,000 Bar. To form a lamellae globule structure.
(d) 아스콜빈산 성분을 첨가하여 균질하게 한 후, 2차 고압미세균질기를 통과시켜 미세다중 라멜라 소구체화시켰다.(d) Homogenized by addition of the ascorbic acid component, and then passed through a secondary high pressure microhomogenizer to micromultiple lamellar glomeruli.
실험예 2Experimental Example 2
제조예 1, 2, 3에서 제조한 미세다중 라멜라 소구체 및 기존에 사용중인 미백 원료인 알부틴, 아스콜빈산을 미세다중 라멜라 소구체한 제조예 4, 5에 대하여 세포독성 비교실험을 하였다. Trypsinization에 의하여 회수한 Transformed Mouse Fibroblast L929 세포를 2% BCS가 함유된 DMEM으로 suspension시킨 후 96 Well Tissue Culture Plate의 각각의 well에 세포 현탁액(2,500∼3,000cell/well)100mL을 접종한 다음, 37℃에서 5% CO2 조건으로 2일간 배양하였다. 배양이 끝나면 각 well에 100mL의 Neutral Red 용액(50㎎/mL)을 첨가하여 3시간 동안 반응시켰다.Cytotoxicity was compared with the micromultiple lamellar globules prepared in Preparation Examples 1, 2, and 3, and the preparations 4 and 5 with the fine multi-lamellar globules of arbutin and ascorbic acid, which are whitening raw materials, were used. Transformed Mouse Fibroblast L929 cells recovered by Trypsinization were suspended in DMEM containing 2% BCS, and then inoculated with 100 mL of cell suspension (2,500 to 3,000 cells / well) in each well of a 96 Well Tissue Culture Plate. Incubated at 5% CO2 for 2 days. After incubation, 100 mL of Neutral Red solution (50mg / mL) was added to each well and reacted for 3 hours.
Neutral Red가 완전히 Plasma Membrane을 통과하여 살아있는 세포 또는 손상 받지 않은 세포의 Lysosome에 농축된 후 1.0% Formalin/1.0% CaCl2 100mL로 고정화한 다음 1.0% Acetic acid/50% Ethanol 이용액을 사용하여 세포내의 Neutral Red를 추출하였다. 추출된 Neutral Red를 ELISA Reader를 이용하여 540㎚에서 농도별로 세포독성을 측정하였다.Neutral Red was completely passed through the Plasma Membrane and concentrated in Lysosomes of living or intact cells, immobilized with 100 mL of 1.0% Formalin / 1.0% CaCl2 and then intracellular Neutral Red using 1.0% Acetic acid / 50% Ethanol solution. Was extracted. The extracted Neutral Red was measured for cytotoxicity by concentration at 540 nm using ELISA Reader.
실험예 2의 비교실험을 통해 제조예 1, 2, 3에 의한 미세다중 라멜라 소구체의 NR50값이 제조예 4, 5에 의한 미세다중 라멜라 소구체화한 것보다 매우 안전함을 알 수 있었다.The comparative experiments of Experimental Example 2 showed that the NR 50 value of the micromultiple lamellar globules according to Preparation Examples 1, 2 and 3 was much safer than that of the micromultiple lamellar glomeruli according to Preparation Examples 4 and 5.
본 발명의 미세다중 라멜라 소구체(제조예 3)를 함유한 영양화장수의 처방예를 처방예 1에 표시하였다.The prescription example of the nutrient cosmetics containing the micromultiple lamellar glomeruli (manufacturing example 3) of this invention is shown in the prescription example 1.
처방예 1Prescription Example 1
미세다중 라멜라 소구체(제조예 3)를 함유한 화장료 중 영양화장수의 처방예는 다음과 같다.Prescription examples of nutrient cosmetics in cosmetics containing micromultiple lamellar globules (Manufacturing Example 3) are as follows.
본 발명의 색차계를 이용한 미백효과 측정 및 실제사용자 테스트에 적용한 비교예를 비교예 1, 2에 표시하였다.Comparative examples applied to the whitening effect measurement and the actual user test using the color difference meter of the present invention are shown in Comparative Examples 1 and 2.
비교예 1Comparative Example 1
알부틴을 함유한 화장료 중 영양화장수이 비교예는 다음과 같다.The comparative example of nutrient cosmetics in the cosmetics containing arbutin is as follows.
비교예 2Comparative Example 2
아스콜빈산을 함유한 화장료 중 영양화장수이 비교예는 다음과 같다.The comparative example of nutrient cosmetics in the cosmetics containing ascolic acid is as follows.
실험예 3 : 색차계를 이용한 미백 효과 평가Experimental Example 3: Evaluation of the whitening effect using a color difference meter
본 발명의 화장료의 미백효과를 색차계(COLORIMETER CR-1000, MINOLTA사, 미국)를 이용하여 평가를 하였다. 평가방법으로 사람의 피부와 동일한 갈색 기니아 피그(Tortoiseshell guinea pigs)의 등을 제모한 후 3×3cm의 정방형의 크기에 크세논램프(파장290-400nm)로 자외선(UVB)을 조사하였다. 조사기간은 1.25mW/cm2, 6분으로 하여 1일 1회로 3일간 조사하였다. 그 후 처방예 1의 영양화장수와 알부틴(비교예 1), 아스콜빈산(비교예 2)으로 대체한 영양화장수를 도포하여 평가하였다.도포시기는 자외선 조사 후 색소침착이 가장 높은 14일 후에 도포하여 개선효과를 평가하였다. 도포횟수는 1일 1회로 30일 동안 연속하여 발라주었다. 이 색차계에 의한 평가는 주로 △L*값(명도, lighteness)으로 측정하였다. 측정식은 아래와 같고 실험결과는 도 2에 표시하였다.The whitening effect of the cosmetic of the present invention was evaluated using a color difference meter (COLORIMETER CR-1000, MINOLTA, USA). As an evaluation method, the hair of brown guinea pigs (Tortoiseshell guinea pigs), which is the same as human skin, was epilated, and then UV (UVB) was irradiated with a xenon lamp (wavelength 290-400 nm) in a square size of 3 × 3 cm. The irradiation period was 1.25 mW / cm 2 and 6 minutes, which was conducted once a day for 3 days. Subsequently, the nutritional cosmetics of Formula 1, arbutin (Comparative Example 1), and nutrient cosmetics replaced with ascorbic acid (Comparative Example 2) were applied. The application period was applied 14 days after the highest pigmentation after UV irradiation. The improvement effect was evaluated. The number of application was applied continuously for 30 days once a day. Evaluation by this color difference meter was mainly measured by (DELTA) L * value (brightness, lighteness). The measurement formula is as follows and the experimental results are shown in FIG.
△L*=도포개시시의 L*값 - 도포 후 X일 후의 L*값△ L * = L * value at the time of application-L * value after X days after application
위 실험결과에 의하여, 처방예 1이 비교예 1, 2에 비하여 색소침착의 조기 개선효과가 있음을 확인할 수 있었다.As a result of the above experiment, it was confirmed that Formulation Example 1 has an early improvement effect of pigmentation compared to Comparative Examples 1 and 2.
실험예 4 : 사용자 테스트를 통한 미백 효과 평가Experimental Example 4: Evaluation of the whitening effect through a user test
또한, 본 발명의 영양화장수의 미백효과를 실제 사용 테스트를 통하여 평가하였다. 처방예 1의 미세다중 라멜라 소구체(제조예 3) 25 중량%를 함유하고 있는 영양화장수와 알부틴(비교예 1), 아스콜빈산(비교예 2)으로 대체한 영양화장수를 사용하였다. 30명의 30-50대 여성을 처방예 1과 비교예 1, 2의 영양화장수를 매일 아침 저녁 2회씩 세안 후 영양화장수 적당량을 안면에 2개월간 연속적으로 바르게 하였다. 2개월 후 육안평가를 실시하였다. 판정기준(표 3)과 실험결과 (표 4, 5)는 다음과 같다.In addition, the whitening effect of nutritional longevity of the present invention was evaluated through a practical use test. Nutrient cosmetics containing 25% by weight of the micromultiple lamellar glomeruli (Preparation Example 3) of Formulation Example 1 were replaced with arbutinic acid (Comparative Example 1) and ascorbic acid (Comparative Example 2). Thirty women in their 30s and 50s were rinsed twice each morning for the nourishing cosmetics of Prescription 1 and Comparative Examples 1 and 2, and the right amount of nourishing cosmetics was applied to the face continuously for 2 months. Two months later, a visual evaluation was conducted. Judgment criteria (Table 3) and test results (Tables 4 and 5) are as follows.
※ OS: 지성 피부 타입, NS: 정상 피부 타입, DS: 건성 피부 타입※ OS: oily skin type, NS: normal skin type, DS: dry skin type
위 실험결과를 통하여, 미세다중 라멜라 소구체를 함유한 본 발명(처방예 1)은 비교예 1, 2에 비하여 10∼20%의 상승된 미백 효과를 나타낸다는 것이 증명되었다.Through the above experimental results, it was proved that the present invention (prescription example 1) containing the micromultiple lamellar globules showed an increased whitening effect of 10 to 20% compared to the comparative examples 1 and 2.
본 발명은 피부 활성 미용 성분과 오일 성분을 리포좀화시킨 미세다중 라멜라 소구체(Nano Multiple Lamella Sphere)를 포함하는 미백 화장료 조성물에 관한 것으로서, 일반적인 미세다중 라멜라 소구체를 포함하는 화장료 조성물의 우수한 미용성분 침투력과 지속성을 그대로 유지하는 동시에 피부활성 성분과 오일 성분을 추가하여 기존 미백 원료를 이용한 화장료 조성물에 비해 훨씬 상승된 미백 효과와 우수한 피부 안정성을 나타낸다.The present invention relates to a whitening cosmetic composition comprising a nano-multiple lamella spheres liposome-ized skin active cosmetic ingredients and oil components, excellent cosmetic components of a cosmetic composition comprising a general micro-multiple lamellar spheres While maintaining penetration and persistence, skin active ingredients and oils are added to the skin, resulting in a much higher whitening effect and superior skin stability compared to cosmetic compositions using conventional whitening ingredients.
Claims (9)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020020008280A KR20030068698A (en) | 2002-02-16 | 2002-02-16 | Whitening cosmetic composition containing nano multiple lamella sphere and method of producing the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020020008280A KR20030068698A (en) | 2002-02-16 | 2002-02-16 | Whitening cosmetic composition containing nano multiple lamella sphere and method of producing the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20030068698A true KR20030068698A (en) | 2003-08-25 |
Family
ID=32221549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020020008280A Ceased KR20030068698A (en) | 2002-02-16 | 2002-02-16 | Whitening cosmetic composition containing nano multiple lamella sphere and method of producing the same |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20030068698A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20070089459A (en) * | 2006-02-28 | 2007-08-31 | (주)아모레퍼시픽 | Skin whitening composition containing cholesteryl hemisuccinate-based nanocarrier extract as an active ingredient |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR960009644A (en) * | 1994-08-12 | 1996-03-22 | 이헌조 | TV audio signal caption processing device and method |
| KR970001640A (en) * | 1995-06-20 | 1997-01-24 | Front roller feeder | |
| JPH10231229A (en) * | 1997-02-19 | 1998-09-02 | Nippon Fine Chem Co Ltd | Cosmetics |
| KR19990025583A (en) * | 1997-09-12 | 1999-04-06 | 유상옥 | Cosmetic composition stabilized oil-soluble active substance |
| KR19990078610A (en) * | 1999-07-03 | 1999-11-05 | 김현준 | Skin Care Composition For Improvement Of The Water-retaing Capacity Of The Skin And Restoration Of a Damaged Skin |
| KR20000055082A (en) * | 1999-02-03 | 2000-09-05 | 안용찬 | multilamellar emulsion cosmetics containing pseudoceramides |
-
2002
- 2002-02-16 KR KR1020020008280A patent/KR20030068698A/en not_active Ceased
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR960009644A (en) * | 1994-08-12 | 1996-03-22 | 이헌조 | TV audio signal caption processing device and method |
| KR970001640A (en) * | 1995-06-20 | 1997-01-24 | Front roller feeder | |
| JPH10231229A (en) * | 1997-02-19 | 1998-09-02 | Nippon Fine Chem Co Ltd | Cosmetics |
| KR19990025583A (en) * | 1997-09-12 | 1999-04-06 | 유상옥 | Cosmetic composition stabilized oil-soluble active substance |
| KR20000055082A (en) * | 1999-02-03 | 2000-09-05 | 안용찬 | multilamellar emulsion cosmetics containing pseudoceramides |
| KR19990078610A (en) * | 1999-07-03 | 1999-11-05 | 김현준 | Skin Care Composition For Improvement Of The Water-retaing Capacity Of The Skin And Restoration Of a Damaged Skin |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20070089459A (en) * | 2006-02-28 | 2007-08-31 | (주)아모레퍼시픽 | Skin whitening composition containing cholesteryl hemisuccinate-based nanocarrier extract as an active ingredient |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100825839B1 (en) | Skin whitening agent | |
| EP1806120B1 (en) | Composition for prevention or alleviation of pigmentation | |
| WO2011122840A2 (en) | Inhibitor for melanin, and cosmetic composition containing same | |
| US20080214669A1 (en) | Composition and Method For Treating Hyperpigmented Skin | |
| WO2013187574A1 (en) | Skin-whitening cosmetic composition | |
| KR102142311B1 (en) | Skin external composition comprising tangeretin | |
| JP2003277223A (en) | Matrix metalloprotease inhibitor and skin elasticity- retaining cosmetic | |
| KR100896697B1 (en) | Method for promoting percutaneous absorption of rhubarb extract by high pressure emulsification technology and external skin composition for whitening using the same | |
| US9492492B2 (en) | Compositions comprising Lilium martagon extracts and uses thereof | |
| US8293293B2 (en) | Compositions comprising Lilium martagon extracts and uses thereof | |
| JP2001019607A (en) | Skin cosmetic | |
| KR20050117958A (en) | Topical nano liposome formulation including extracted purified herbal mixture and whitening cosmetics using this formulation | |
| KR101322850B1 (en) | The cosmetic composition for pore-minimizing and inhibition of Sebum Secretion containing the extract of leaves of Mentha arvensis var. piperascens, wheat bud, and Platycodon grandiflorum | |
| KR20030068698A (en) | Whitening cosmetic composition containing nano multiple lamella sphere and method of producing the same | |
| KR102842724B1 (en) | Cosmetic composition for relieving skin irritation and activating whitening using mixed extracts of Centella asiatica and Portulaca vulgaris | |
| KR102566894B1 (en) | Cosmetic composition having anti-oxidant, anti-inflammatory and skin whiening effects which comprise DKMEX | |
| JP2000256174A (en) | Cosmetic composition | |
| JP2002114700A (en) | Melanocyte activator | |
| JP4959104B2 (en) | Whitening agent and external preparation for skin | |
| JPH11124313A (en) | External preparation for skin whitening | |
| JP4959103B2 (en) | Whitening agent and external preparation for skin | |
| KR20250141867A (en) | Cell targeted polymer self-assembly nanomicelles, and method of preparing the same | |
| EP2465489B1 (en) | Compositions comprising lilium martagon extracts and uses thereof | |
| JP2002255780A (en) | Skin care preparation | |
| KR20070065665A (en) | Whitening cosmetic composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20020216 |
|
| PA0201 | Request for examination | ||
| PG1501 | Laying open of application | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20040430 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20040730 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20040430 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |